[{"thread": {"domain_rank": null, "replies_count": 0, "url": "http://omgili.com/ri/.wHSUbtEfZTEOzG0ily41M6pkV3Re9LvAIYzEPNcjIWI3BcLFMnQ7dYU4nVE3CjEjlvzHbQAmz_Iux9Zrg2vVi.wBtgxUEzStbOEQIu1UvEv6w149EzMQ.sPH9wsHjPrx6TNDL1Jsz0mGhRs.5gjOA--", "title": "Liver Fibrosis Therapeutic Pipeline Market Review, H1 2017", "site_type": "blogs", "social": {"pinterest": {"shares": 0}, "stumbledupon": {"shares": 0}, "gplus": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"comments": 0, "shares": 0, "likes": 0}}, "site_section": "https://wiseguyresearch.wordpress.com", "spam_score": 0.0, "section_title": "Liver Fibrosis Therapeutic Pipeline Market Review, H1 2017 \u2013 Site Title", "site": "wordpress.com", "site_full": "wiseguyresearch.wordpress.com", "performance_score": 0, "uuid": "f2f4eaf82895fe0ab896219e830e6790f01a3392", "published": "2017-04-17T11:25:54.000+03:00", "site_categories": [], "country": "US", "title_full": "Liver Fibrosis Therapeutic Pipeline Market Review, H1 2017", "participants_count": 1, "main_image": null}, "url": "http://omgili.com/ri/.wHSUbtEfZTEOzG0ily41M6pkV3Re9LvAIYzEPNcjIWI3BcLFMnQ7dYU4nVE3CjEjlvzHbQAmz_Iux9Zrg2vVi.wBtgxUEzStbOEQIu1UvEv6w149EzMQ.sPH9wsHjPrx6TNDL1Jsz0mGhRs.5gjOA--", "title": "Liver Fibrosis Therapeutic Pipeline Market Review, H1 2017", "highlightTitle": "", "external_links": [], "crawled": "2017-04-17T11:25:54.000+03:00", "language": "english", "entities": {"locations": [], "persons": [], "organizations": [{"name": "companies /universities /institutes", "sentiment": "none"}, {"name": "healthcare", "sentiment": "none"}]}, "rating": null, "highlightText": "", "ord_in_thread": 0, "uuid": "f2f4eaf82895fe0ab896219e830e6790f01a3392", "published": "2017-04-17T11:25:54.000+03:00", "author": "wiseguyresearch", "text": "GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1184721-liver-fibrosis-pipeline-review-h1-2017 \n \nReport Highlights \nPharmaceutical and Healthcare latest pipeline guide Liver Fibrosis \u2013 Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\n \nThe Liver Fibrosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 1, 46 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 8 molecules, respectively.\n \nLiver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.\n \nScope \n\u2013 The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Fibrosis (Gastrointestinal).\n\u2013 The pipeline guide reviews pipeline therapeutics for Liver Fibrosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.\n\u2013 The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.\n\u2013 The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.\n\u2013 The pipeline guide reviews key companies involved in Liver Fibrosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.\n\u2013 The pipeline guide evaluates Liver Fibrosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.\n\u2013 The pipeline guide encapsulates all the dormant and discontinued pipeline projects.\n\u2013 The pipeline guide reviews latest news related to pipeline therapeutics for Liver Fibrosis (Gastrointestinal)\n \nReasons to buy \n\u2013 Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.\n\u2013 Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.\n\u2013 Find and recognize significant and varied types of therapeutics under development for Liver Fibrosis (Gastrointestinal).\n\u2013 Classify potential new clients or partners in the target demographic.\n\u2013 Develop tactical initiatives by understanding the focus areas of leading companies.\n\u2013 Plan mergers and acquisitions meritoriously by identifying key players and it\u2019s most promising pipeline therapeutics.\n\u2013 Formulate corrective measures for pipeline projects by understanding Liver Fibrosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.\n\u2013 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.\n\u2013 Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.\n \nTable of Content: Key Points \nTable of Contents 2\nIntroduction 5\nLiver Fibrosis \u2013 Overview 6\nLiver Fibrosis \u2013 Therapeutics Development 7\nLiver Fibrosis \u2013 Therapeutics Assessment 18\nLiver Fibrosis \u2013 Companies Involved in Therapeutics Development 30\nLiver Fibrosis \u2013 Drug Profiles 53\nLiver Fibrosis \u2013 Dormant Projects 177\nLiver Fibrosis \u2013 Discontinued Products 180\nLiver Fibrosis \u2013 Product Development Milestones 181\nAppendix 191\n\u2026Continued \n\nACCESS REPORT @ https://www.wiseguyreports.com/reports/1184721-liver-fibrosis-pipeline-review-h1-2017 "}]